RTRyo Tsunashima

Ryo Tsunashima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryo Tsunashima has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Seung Jin Kim

    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita, Japan

    10 shared publications
  • Yasuto Naoi

    Kyoto Prefectural University of Medicine: Kyoto Furitsu Ika Daigaku

    9 shared publications
  • Kenzo Shimazu

    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita, Japan

    7 shared publications
  • Shinzaburo Noguchi

    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

    7 shared publications
  • Atsushi Shimomura

    Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    6 shared publications
  • Naomi Maruyama

    Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    6 shared publications

Latest Publications

  • Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device

    by Akira Watanabe, Sae Kitano, Chikage Kato, Ryo Tsunashima, Chise Matsui, Saya Matsumoto, Ikoi Omatsu, Eiichi Konishi, Yoshiaki Sota, Takumi Shiraishi, et al.

    Background The growing need for immunohistochemical and genetic testing often results in shortage of breast cancer vacuum-assisted biopsy (VAB) samples. Their value has become increasingly important with improvements in neoadjuvant chemotherapy outcomes. To enhance diagnostic utility, the longitudinal division of a single VAB sample can provide matched “mirror samples.” We adapted a prostate biopsy tissue divider for use with 10G-VAB breast cancer specimens and evaluated its feasibility for pathological and molecular analyses. Methods A total of 100 10G-VAB specimens from 32 patients were longitudinally bisected using the dividing tool. The pathological concordance between the paired mirror samples was assessed by histological examination. Their suitability for DNA and mRNA analyses was also evaluated by next-generation gene panel sequencing and microarray-based gene expression profiling. Results Of the 72 samples confirmed to contain malignant tissue, 70 (97.2%) exhibited high pathological concordance between the mirror pairs. The remaining two samples (2.8%), derived from the tumor margins, exhibited discordant histological findings. Moreover, gene panel testing (n = 8) and comprehensive gene expression profiling using microarray (n = 8) were successfully performed on all of the mirror samples (n = 16). Conclusion The longitudinal division of breast cancer VAB tissue using a specialized dividing device results in anatomically matched mirror samples with high pathological fidelity. These specimens are suitable for advanced molecular diagnostics, thus providing a valuable tool for clinical practice and translational studies.

  • Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies

    by Aya Imai, Ryo Tsunashima, Yu Hidaka, Sae Kitano, Chikage Kato, Akira Watanabe, Midori Morita, Koichi Sakaguchi, Yoshiaki Sota, Masahiko Suzuki, et al.

    Background In recent years, multigene assays have become indispensable tools for predicting the recurrence risk of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and guiding adjuvant chemotherapy decisions. Curebest™ 95GC Breast (95GC), developed in 2011 as a domestically produced multigene assay for postoperative recurrence prediction, has been commercially available since 2013. Since 2021, five validation studies evaluating the predictive performance 95GC have been published. This study presents an integrated analysis of these studies to validate the prognostic utility of 95GC further. Methods The integrated analysis included 719 real-world cases of luminal-type node-negative breast cancer patients who underwent adjuvant hormone therapy alone without extended endocrine treatment. In addition, an expanded cohort incorporating 294 cases from Western patients within the GEO public database was analyzed, resulting in a total of 1013 cases. Results Among the 719 real-world cases, 550 (76.5%) were classified into the 95GC Low-risk group, demonstrating a significantly superior prognosis compared to the High-risk group (P < 1.00e−12). The 5-year distant recurrence-free survival (DRFS) rate in the Low-risk group was approximately 98%, with consistent findings observed in the expanded cohort. Furthermore, an analysis of 754 CEL files using 21GC (a proxy for Oncotype DX®) identified 318 cases (42.2%) as the 21GC intermediate risk. 95GC successfully stratified these cases into two prognostically distinct subgroups. Conclusions These findings underscore the clinical utility of 95GC in safely omitting chemotherapy for Low-risk patients with good prognosis and in further stratifying the 21GC Intermediate-risk cases, thereby contributing to personalized treatment strategies.


  • Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer

    by Sae Kitano, Ryo Tsunashima, Chikage Kato, Akira Watanabe, Yoshiaki Sota, Saya Matsumoto, Midori Morita, Koichi Sakaguchi, Yasuto Naoi

    Background The mechanism of late recurrence (LR) of estrogen receptor (ER)-positive breast cancer remains unclear, as previous studies have separately investigated “gene expression profiles” and “clinicopathological factors.” Thus, this study aimed to evaluate the predictive capability of LR by combining the two independent factors of gene expression profiles (42-gene classifier: 42GC) and clinicopathological factors (Clinical Treatment Score post-5 years: CTS5) in multiple large cohorts. Methods We analyzed microarray CEL file data downloaded from public databases of 28 global cohorts. A total of 2,454 patients with ER-positive breast cancer were analyzed for 42GC, and 1,263 of these, with complete clinicopathological data were analyzed for CTS5. Results In the analysis of recurrent patients, the 42GC LR and CTS5 low-risk group tended to have LR. Notably, in the analysis of patients with and without recurrence, the highest LR rate beyond 5 years was observed in the CTS5 high-risk group. The combination of the 42GC and CTS5 high-risk groups showed the highest LR rate (16.9%), significantly exceeding that of the 42GC non-LR (NLR) and CTS5 low-risk combination (5.41%) (p = 0.038, odds ratio = 3.53). Furthermore, incorporating a third factor, 95GC, potentially reduced the number of patients prioritized for extended hormonal therapy for approximately one-quarter of patients. Conclusions Results confirmed that the two factors, gene expression profiles and clinicopathological factors, affect the time of recurrence. It also showed that the biological predisposition for LR (CTS5 low-risk) differed from the high LR rate (CTS5 high-risk). In clinical practice, patients with the 42GC LR and CTS5 high-risk combination should be prioritized for extended hormonal therapy. The addition of CTS5 and 95GC to 42GC allows for better risk classification of LR.


  • Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues

    by Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi

    Background EndoPredict® (EP) is a multigene assay to predict distant recurrence risk in luminal breast cancer. EP measures the expression of 12 genes in primary tumor by qRT-PCR from formalin-fixed paraffin-embedded (FFPE) tissues and calculates EP risk score that indicates the risk of distant recurrence. We evaluated the performance of EP in predicting distant recurrence risk using microarray data from fresh frozen (FF) tissues. We also examined the applicability of EP to microarray data from FFPE tissues. Methods We analyzed the publicly available data of 431 node-negative and 270 node-positive patients with luminal breast cancer who received endocrine therapy alone. We evaluated the prognostic value of EP using microarray data from FF tissues. Next, we created an algorithm to calculate EP risk score using microarray data from FFPE tissues. We examined the correlation coefficient of EP risk score and concordance rate of EP risk high/low using microarray data from FFPE/FF tissue pairs in a validation set of 39 patients. Results In 431 node-negative patients, the distant recurrence-free survival (DRFS) rate was significantly worse in those with high EP risk scores (P = 3.68 × 10−6, log-rank). The 5-year DRFS was 95.2% in those with low EP risk score. In the validation set, the correlation coefficient of EP risk score was 0.93 and the concordance rate of EP risk high/low was 91.7%. Conclusions EP using microarray data from FF tissues was useful in predicting distant recurrence risk in luminal breast cancer, and EP might be utilized in microarray data from FFPE tissues.


  • Open Access

    Clarification attempt of the mechanism of late recurrence by micro- and macro-analyses in estrogen receptor-positive breast cancer

    by Sae Kitano, Ryo Tsunashima, Chikage Kato, Akira Watanabe, Yoshiaki Sota, Saya Matsumoto, Midori Morita, Koichi Sakaguchi, Yasuto Naoi

    Purpose The mechanism of late recurrence (LR) of estrogen receptor (ER)-positive breast cancer remains unclear. As prediction models for LR of ER-positive breast cancer, 42-gene classifier (42GC), which analyzes “micro-factors (gene expression patterns)” and the Clinical Treatment Score post-5 years (CTS5), which analyzes “macro-factors (clinicopathological factors)”, were developed; however, improving the accuracy of these models is desirable. We aimed to clarify the mechanism and develop a new prediction model by combining 42GC and CTS5. Methods We selected 2,454 patients with ER-positive breast cancer from public microarray databases. We performed recurrence prognostic analysis using 42GC and CTS5. Results In “the basic research” for recurrent patients (n = 347), the 42GC LR and CTS5 low-risk groups tended to have LR. In “the clinical research” for recurrence-free patients 5 years after surgery (n = 671), the 42GC LR and CTS5 high-risk group had a significantly higher LR rate after 5 years (16.9%) than the 42GC non-LR and CTS5 low-risk group (5.41%) (p = 0.037). Conclusion In “the basic research,” we found that both micro-and macro-factors were associated with the mechanisms of early recurrence and LR. Meanwhile, in “the clinical research,” we found that the mechanistic tendency toward LR (the CTS5 low-risk group) differed from the high rate of LR (the CTS5 high-risk group). Therefore, differentiating between the biological mechanisms elucidated in “the basic research” and the decision-making process concerning extended hormonal therapy in “the clinical research” is necessary. These findings propose the development of a novel prediction model for LR.

  • Open Access

    Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression

    by Masafumi Shimoda, Ami Hori, Jack R. Wands, Ryo Tsunashima, Yasuto Naoi, Tomohiro Miyake, Tomonori Tanei, Naofumi Kagara, Kenzo Shimazu, Seung Jin Kim, et al.

    Although prognostic markers for early estrogen receptor (ER)‐positive breast cancer have been extensively developed, predictive markers for adjuvant endocrine therapy are still lacking. Focusing on the mechanisms underlying endocrine resistance, we investigated whether the endocrine sensitivity of ER‐positive breast cancer cells was correlated with the expression of aspartate‐β‐hydroxylase (ASPH), which is involved in the development of hepatocellular carcinoma. ASPH expression in ER‐positive and tamoxifen‐resistant breast cancer cells was upregulated by the MAPK and phosphoinositide‐3 kinase (PI3K) pathways, which both play pivotal roles in endocrine resistance. In the clinical setting, ASPH expression was negatively correlated with recurrence‐free survival of luminal B breast cancer patients that received adjuvant endocrine therapy, but not in patients that did not receive adjuvant endocrine therapy. Luminal B breast cancer is one of the intrinsic molecular subtypes identified by the Prediction Analysis of Microarray 50 (PAM50) multiple gene classifier, and because of its poor response to endocrine therapy, chemotherapy in addition to endocrine therapy is generally required after surgical resection. Our results suggest that the endocrine sensitivity of luminal B breast cancer can be assessed by examining ASPH expression, which promotes the consideration of a prospective study on the association between ASPH expression at the mRNA and protein levels in luminal B breast cancer and subsequent response to endocrine therapy.


  • Construction of multi-gene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers

    by Ryo Tsunashima, Yasuto Naoi, Naofumi Kagara, Masashi Shimoda, Atsushi Shimomura, Naomi Maruyama, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi


  • Development of a prediction model for lymph node metastasis in luminal A subtype breast cancer: The possibility to omit sentinel lymph node biopsy

    by Chiaki Nakauchi, Yasuto Naoi, Kenzo Shimazu, Ryo Tsunashima, Minako Nishio, Naomi Maruyama, Atsushi Shimomura, Naofumi Kagara, Masashi Shimoda, Seung Jin Kim, et al.


  • 72-Gene Classifier for Predicting Prognosis of Estrogen Receptor–Positive and Node-Negative Breast Cancer Patients Using Formalin-Fixed, Paraffin-Embedded Tumor Tissues

    by Minako Nishio, Yasuto Naoi, Ryo Tsunashima, Chiaki Nakauchi, Naofumi Kagara, Masafumi Shimoda, Atsushi Shimomura, Naomi Maruyama, Kenzo Shimazu, Seung Jin Kim, et al.


  • Open Access

    Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer

    by Y. Sota, Y. Naoi, R. Tsunashima, N. Kagara, K. Shimazu, N. Maruyama, A. Shimomura, M. Shimoda, K. Kishi, Y. Baba, et al.

    The aim of this study was to construct a novel prediction model for the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) using immune-related gene expression data. DNA microarray data were used to perform a gene expression analysis of tumor samples obtained before NAC from 117 primary breast cancer patients. The samples were randomly divided into the training (n = 58) and the internal validation (n = 59) sets that were used to construct the prediction model for pCR. The model was further validated using an external validation set consisting of 901 patients treated with NAC from six public datasets. The training set was used to construct an immune-related 23-gene signature for NAC (IRSN-23) that is capable of classifying the patients as either genomically predicted responders (Gp-R) or non-responders (Gp-NR). IRSN-23 was first validated using an internal validation set, and the results showed that the pCR rate for Gp-R was significantly higher than that obtained for Gp-NR (38 versus 0%, P = 1.04E−04). The model was then tested using an external validation set, and this analysis showed that the pCR rate for Gp-R was also significantly higher (40 versus 11%, P = 4.98E−23). IRSN-23 predicted pCR regardless of the intrinsic subtypes (PAM50) and chemotherapeutic regimens, and a multivariate analysis showed that IRSN-23 was the most important predictor of pCR (odds ratio = 4.6; 95% confidence interval = 2.7–7.7; P = 8.25E−09). The novel prediction model (IRSN-23) constructed with immune-related genes can predict pCR independently of the intrinsic subtypes and chemotherapeutic regimens.